We are live on ! Find out more

Veracyte

VCYT

Market cap $3.49B

43.40 USD

+1.93

4.65%

At close Updated Aug 25, 1:35 PM EDT

1 day

4.65%

5 days

3.53%

1 month

-21.96%

3 months

-1.83%

6 months

21.5%

Year to date

2.38%

1 year

46.87%

5 years

-2.23%

10 years

717.33%

About: Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder).

Employees: 755

Healthcare Diagnostics & Research

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 55.2%

Neutral 34.5%

Negative 10.3%

Zacks Investment Research

VCYT Drops 25.3% in the Past Month. Is the Sell-Off an Opportunity?

Veracyte's 25.3% sell-off improves the entry price as strong core test demand and earnings growth face valuation, reimbursement and launch risks.

VCYT Drops 25.3% in the Past Month. Is the Sell-Off an Opportunity?

Zacks Investment Research

Down 30.2% in 4 Weeks, Here's Why Veracyte (VCYT) Looks Ripe for a Turnaround

Veracyte (VCYT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Down 30.2% in 4 Weeks, Here's Why Veracyte (VCYT) Looks Ripe for a Turnaround

Veracyte: Diagnostics With Favorable Economics

Veracyte's core tests are Decipher and Afirma. Both of these tests are producing double-digit growth with improving margins. I think that bodes well for VCYT's potential as a long-term cash flow machine. Moreover, VCYT's Prosigna and TrueMRD add more long-term upside, which management hasn't yet included in its recent 2026 testing-revenue guidance.

Veracyte: Diagnostics With Favorable Economics

Veracyte: Core Growth Funds Prosigna And TrueMRD

Veracyte (VCYT) is evolving into a self-funded cancer diagnostic platform, leveraging clinical evidence, specialist relationships, and reimbursement infrastructure. Q2 2026 results showed 15% revenue growth, 23% adjusted EBITDA growth, and 29.2% EBITDA margin, with robust cash generation and no funded debt. Prosigna and TrueMRD launches offer significant upside, as 2026 guidance excludes their contributions, while Decipher and Afirma drive core growth and margin expansion.

Veracyte: Core Growth Funds Prosigna And TrueMRD

Veracyte, Inc. (VCYT) Q2 2026 Earnings Call Transcript

Veracyte, Inc. (VCYT) Q2 2026 Earnings Call Transcript

Veracyte, Inc. (VCYT) Q2 2026 Earnings Call Transcript

Zacks Investment Research

Veracyte (VCYT) Q2 Earnings and Revenues Surpass Estimates

Veracyte (VCYT) came out with quarterly earnings of $0.54 per share, beating the Zacks Consensus Estimate of $0.43 per share. This compares to earnings of $0.44 per share a year ago.

Veracyte (VCYT) Q2 Earnings and Revenues Surpass Estimates

Veracyte Announces Second Quarter 2026 Financial Results

Grew total revenue to $150.3 million and testing revenue to $145.7 million , representing increases of 15% and 19% year-over-year, respectively Conference call and webcast today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif.

Veracyte Announces Second Quarter 2026 Financial Results

Veracyte to Participate in Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., July 28, 2026 (GLOBE NEWSWIRE) -- Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that it will be participating in the following investor conferences:

Veracyte to Participate in Upcoming Investor Conferences

Zacks Investment Research

Earnings Preview: Veracyte (VCYT) Q2 Earnings Expected to Decline

Veracyte (VCYT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Veracyte (VCYT) Q2 Earnings Expected to Decline

Artisan Mid Cap Fund Q2 2026 Performance Review

Artisan Mid Cap Fund portfolio generated strong absolute returns and outpaced the Russell Midcap® Growth Index. Within IT, several semiconductor holdings produced exceptional returns, with multiple positions rising more than 100% during the period. During the quarter, we initiated new positions in Entegris, Modine Manufacturing and C.H. Robinson Worldwide.

Artisan Mid Cap Fund Q2 2026 Performance Review

See News Rankings

Price charts implemented using Lightweight Charts™